This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Measure of benefits used in the economic analysis
The three main outcome measures used in the analysis were the number of acute episodes, number of euthymic days and quality-adjusted life-years (QALYs). Other model outputs, such as the number of manic episodes, number of depressive episodes, days in manic state and days in depression state, were also reported. No discount rate was applied because of the short time horizon.
Direct costs
The analysis was carried out from the perspective of the third-party payer. It included the direct medical costs of drugs for maintenance treatment, drug and hospitalisation for the treatment of acute manic and depressive episodes, and resources of contacts with health care professionals for monitoring and pathology tests. The unit costs and the quantities of resources used were presented separately. The costs were mainly derived from typical US sources such as drug prices from the Red Book. Resource consumption and other costs came from a survey of psychiatrists and primary care providers from a large, vertically integrated health system in the Midwest. Discounting was not relevant since the costs were incurred during an 18-month time horizon. The price year was 2004.
Statistical analysis of costs
The costs were treated deterministically.
Indirect Costs
The indirect costs were not considered.
Currency

US dollars ($).
Sensitivity analysis
One-and two-way sensitivity analyses were carried out to assess the robustness of the base-case results to variations in clinical and economic inputs. Scenario and threshold analyses were also performed. Most of the clinical inputs were varied. The sources of the alternative values were unclear. An alternative analysis was also carried out by using an alternative source of clinical data on the effectiveness of LAM and by excluding OLA from the comparison. This alternative clinical trial included bipolar patients with a recent depressive episode rather than bipolar patients with a recent bipolar manic episode, as in the primary study.
Estimated benefits used in the economic analysis
In the cohort of 1,000 patients, the number of QALYs was 1,143 (0.762 per patient per year, PPPY) with LAM, 1,103 (0.735 PPPY) with LIT, 1,038 (0.692 PPPY) with no treatment and 1,109 (0.739 PPPY) with OLA.
In the cohort of 1,000 patients, the total number of manic episodes was 1,418 (0.95 PPPY) with LAM, 1,313 (0.88 PPPY) with LIT, 2,644 (1.76 PPPY) with no treatment and 1,030 (0.69 PPPY) with OLA.
In the cohort of 1,000 patients, the total number of depressive episodes was 598 (0.4 PPPY) with LAM, 1,140 (0.76 PPPY) with LIT, 1,822 (1.21 PPPY) with no treatment and 1,080 (0.72 PPPY) with OLA.
In the cohort of 1,000 patients, the total number of acute episodes was 2,016 (1.34 PPPY) with LAM, 2,453 (1.64 PPPY) with LIT, 4,466 (2.98 PPPY) with no treatment and 2,110 (1.41 PPPY) with OLA.
involving a population having recently experienced a manic/mixed (as oppposed to a recently depressed episode) were used.
Validity of estimate of measure of benefit
QALYs were an appropriate benefit measure because they capture the impact of the interventions on quality of life, which is a relevant dimension of health for adults with BD-I. The instrument used to derive utility was reported, but there was little information on the sources of quality of life data. QALYs are comparable with the benefits of other health care interventions. Disease-specific measures were also reported. Discounting was not performed due to the short timeframe of the analysis.
Validity of estimate of costs
The analysis of the costs was consistent with the stated perspective of the study, thus only the direct medical costs were considered. The authors stated that the use of a broader perspective would have been interesting and would have presumably favoured all maintenance treatment strategies. The unit costs and the quantities of resources used were presented separately, which enhances the possibility of replicating the results of the analysis in other settings. Conventional sources for most costs were used. However, the opinions of a panel of experts were used to determine treatment patterns. Some of these assumptions were investigated in the sensitivity analysis. The price year was reported, which will simplify reflation exercises in other time periods.
Other issues
The authors stated that their findings were more favourable than those achieved in a recent appraisal by the National Institute for Health and Clinical Excellence in the UK, which recommended that OLA and valproate should both be prescribed to National Health Service patients. The issue of the generalisability of the study results to other settings was not addressed, but several sensitivity analyses were carried out; these enhance the external validity of the study. The authors discussed the possible explanations for the unfavourable results achieved when the effectiveness data were derived from an alternative bipolar trial population (patients with a recent mixed/manic episode) as opposed to the recently depressed population used in the modelled base case.
It was acknowledged that the main limitations of the analysis were related to simplifying assumptions made in the construction of the decision model. Further, the results of the analysis should be restricted to a population of BD-I patients similar to that included in the primary clinical trials used as the source of effectiveness data. Caution will therefore be required when extrapolating the results of the analysis to patients that were excluded from the trials, for example, rapid cyclers. Finally, the authors pointed out that the time horizon of the model was determined by the follow-up of the clinical trials, but the use of a longer perspective would have been interesting given the characteristics of the disease considered.
Implications of the study
The study results support the use of LAM as well as LIT as maintenance treatment for BD-I patients. The authors suggested that further research should be undertaken to provide more reliable data on utility weights required for the estimation of QALYs in patients with BD-I. Moreover, the comparative effectiveness of the maintenance treatments examined in the study should be evaluated in a head-to-head clinical trial. 
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